Compare ADMA Biologics Inc (ADMA) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.13. The key difference: ADMA Biologics Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADMA | TLT | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | — |
52-Week High | $20.38 | $92.06 |
52-Week Low | $7.60 | $82.05 |
Enterprise Value | $2.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
TLT (iShares 20+ Year Treasury Bond ETF) trades at $82.11, showing minimal daily movement with a 0.08% gain. The technical outlook remains bearish with moving averages signaling strong selling pressure, while oscillators indicate neutral momentum. Recent news highlights pressure from rising Treasury yields and concerns about US debt levels approaching $40 trillion, with institutional activity showing Ferguson Shapiro LLC acquiring 37,900 shares in the latest quarter.
The ETF faces headwinds from rising long-term yields and inflation concerns, though recent dividend payments provide income support. Key risks include Federal Reserve policy uncertainty and escalating geopolitical tensions affecting bond markets. Investors should monitor inflation data and Treasury yield movements for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
